Online

Webinar: A Bond Worth Forming: The Rise of Targeted Covalent Inhibitors

Join us for an expert panel on targeted covalent inhibitors.

Before 2000, many drugs that formed a covalent bond with targets did so non-selectively, which often led to undesired side effects when compared to non-covalent drugs. This led to the belief that covalent inhibitors were not ideal drug candidates, resulting in limited development by the pharmaceutical industry. However, covalent drugs have experienced a remarkable resurgence in the last few years as evidenced by the growing number of approvals by the USFDA, including the 2021 approval of Sotorasib to treat lung cancer, which was recently featured on ACS Webinars.

Today, scientists have designed “warheads” with remarkable functionality that exhibit finely tuned reactivity, which only form covalent bonds when positioned at the desired target. Join a panel of experts as they explore the concept of targeted covalent inhibitors, their application in tackling previously unmanageable targets, and gain valuable insights into the covalent inhibitor landscape.

What you will learn

The theory behind targeted covalent inhibitors and their use against undruggable targets
An overview of the covalent inhibitor landscape based on data from the CAS Content Collection™
Trends of the most used warheads, the proteins they target, and indications they address

Speakers

Written By

Neil Dhawan

CEO and Chief Scientific Officer, Totus Medicines

Written By

Gary Gustafson, Ph.D.

Senior customer success specialist, CAS

Dr. Gary Gustafson spent 25 years as a Medicinal Chemist in the industry and was part of a team that produced the recently FDA-approved drug, Olutasidenib. Since joining CAS in 2019, Gary has helped scientists derive maximum benefit from CAS solutions. Also contributes to the CAS product teams, helping to design new capabilities and enhance existing ones.

He obtained his PhD in Chemistry at Brown University and completed a Postdoctoral Position in Organic Chemistry and Biochemistry at the University of Virginia.

Written By

Angela Zhou

Manager of Scientific Analysis and Insights, CAS

Angela Zhou is an Information Scientist at CAS. She earned her Ph.D. in Molecular Pharmacology and toxicology from University of Southern California. She was further trained as a cell biologist at Johns Hopkins School of Medicine and worked in the area of cancer biology at Harvard Medical School. She was a faculty member at Missouri State University and Denison University prior to joining CAS.